Hospira voluntarily recalled sodium chloride and magnesium sulfate injections due to contamination and labeling error respectively
Hospira, Inc., a U.S based global pharmaceutical and medical device company is voluntarily recalling its sodium chloride and magnesium sulfate injections from market. Hospira has notified its customers to examine their inventory immediately and quarantine, discontinue distribution, and return any stock of the recalled lots. In addition, the manufacturer has instructed its customers to identify and notify anyone who may have received further distributed products. Sodium chloride lot no. 45-110-C6 recalled due to confirmation of presence of human hair by Hospira. The recalled sodium chloride lot is packaged in 250 mL VisIV flex containers and were distributed from December 2014 through January 2015.
Magnesium Chloride injections recalled due to mislabeling. The lot was found to have an incorrect barcode on the primary bag labeling. Incorrect magnesium sulfate barcodes were unlikely to cause patient harm but could cause dealys in treatment. The mislabeled magnesium sulfate lot number 42-120-JT was distributed from October 2014 to January 2015.There have been no reports of adverse events associated with either issue, according to an FDA press release.